临床研究报告数据未大幅改变肾脏病学系统评价的点估计但提高了精确度
该研究基于19项比较艾考糊精与葡萄糖腹膜透析液的随机对照试验,分析在发表数据与作者数据基础上补充临床研究报告(CSR)数据对数据完整性和Meta分析结果的影响。结果显示除生活质量和1-2年净超滤外,补充CSR可提高数据完整性;各结局点估计无统计学显著差异,但严重不良事件和3-6个月净超滤的95%CI变窄,且3-6个月净超滤在补充CSR后点估计显著 favoring 艾考糊精。
要点
- 补充CSR数据可提高系统评价的数据完整性,严重不良事件在发表文献中漏报最多。
- 补充CSR未显著改变各结局的点估计方向,但使严重不良事件和3-6个月净超滤的95%CI变窄。
- 补充CSR后,3-6个月净超滤的点估计显著 favoring 艾考糊精。
核心结论
- 补充CSR数据未大幅改变Meta分析结果,但提高了数据完整性和效应估计的精确度。
- 作者认为获取CSR数据对优化证据合成和指导临床决策具有重要意义。
研究设计与样本
- 研究为一项系统评价与Meta分析的案例报告,纳入19项比较艾考糊精与葡萄糖腹膜透析液的随机对照试验。
- 评估结局包括死亡、腹膜透析技术失败、生活质量、净腹膜超滤(3-6个月和1-2年)、严重不良事件(SAE)、腹膜炎和液体超负荷失控。
- 分别使用发表数据与作者数据(a)以及补充CSR数据(b)重新分析,比较纳入试验数、合并点估计和95%CI。
主要发现
- 除生活质量和1-2年净腹膜超滤外,补充CSR后其余结局可获得更完整数据。
- 各结局在发表数据与作者数据组与补充CSR数据组之间的点估计无统计学显著差异。
- 腹膜炎的点估计在补充CSR后位于无效线两侧,但均无统计学显著性。
- 严重不良事件和3-6个月净腹膜超滤在补充CSR后95%CI变窄。
- 3-6个月净腹膜超滤在补充CSR后点估计显著 favoring 艾考糊精。
临床怎么用
- 作者认为获取CSR数据有助于优化证据合成并指导临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the effect of adding clinical study report (CSR) data to publication and author data on data completeness and meta-analytical results. STUDY DESIGN AND SETTING: Case report of a systematic review with meta-analysis of randomized controlled trials on icodextrin compared to glucose solutions in peritoneal dialysis including 19 clinical trials. We considered the outcomes mortality, peritoneal dialysis technique failure, quality of life, net peritoneal ultrafiltration (at 3-6 months, and 1-2 years), serious adverse events (SAE), peritonitis, and uncontrolled fluid overload. The results for these outcomes were reanalyzed using (a) publication and author data only, then compared with (b) publication and author data with added CSR data. At outcome level, we compared the number of included trials, pooled point estimates (ie, regarding effect direction), and 95% confidence intervals (CIs; ie, regarding overlap and width) between the two groups of trials (a and b). We illustrated the results of our meta-analyses in forest plots and narratively summarized them. RESULTS: Except for two of the eight assessed outcomes (quality of life and net peritoneal ultrafiltration [1-2 years]), more complete data was available when adding CSRs to publication and author data. Point estimates were not statistically significantly different for publication and author data, compared to publication, author, and CSR data, for any outcome. For peritonitis, point estimates were on opposite sides of the line of no effect but remained statistically nonsignificant when adding CSR data. For SAE and net peritoneal ultrafiltration (3-6 months), the width of the 95% CI was narrower when adding CSR data and for net peritoneal ultrafiltration (3-6 months), in addition, the point estimate statistically significantly favored icodextrin when adding CSR data. CONCLUSION: The fraction of publications reporting results varied substantially by outcome, with SAE most under-reported in publications. While the integration of CSR data did not substantially alter meta-analytical results, it enhanced data completeness and precision in effect estimates. Our findings underscore the importance of accessing CSR data to optimize evidence syntheses and inform clinical decision-making. PLAIN LANGUAGE SUMMARY: When researchers want to understand how well a treatment works, they often combine results from several clinical studies in a process called a meta-analysis. Usually, these analyses rely on data published in scientific journals. However, published articles don't always include all the important results. Additional information can sometimes be found in clinical study reports (CSRs), which are detailed documents submitted by pharmaceutical companies to regulatory agencies. In this study, we looked at how including CSR data might affect the results of a meta-analysis. We focused on 19 clinical trials that compared two types of interventions used in peritoneal dialysis for patients with kidney disease: solutions based on icodextrin, a sugar polymer, or on a sugar called glucose. We analyzed several health outcomes such as survival, quality of life, peritoneal ultrafiltration, and complications like infections or kidney function, and serious side effects. First, we analyzed the results using only published articles and information provided by study authors. Then we repeated the analysis, this time adding data from CSRs where available. We compared the number of studies included, the size and direction of treatment effects, and the precision of the results. We found that adding CSRs often provided more complete information, especially for outcomes like serious side effects that were not always reported in journal articles. The overall direction of the results-whether icodextrin was better, worse, or the same-did not change much when CSR data was added. However, the results became more precise in two cases (serious side effects and peritoneal ultrafiltration). In one case, adding CSR data made the benefit of icodextrin statistically significant (peritoneal ultrafiltration). In summary, although adding CSR data did not substantially change the main conclusions, it improved the completeness and accuracy of the results. This shows that using CSRs in research summaries can provide a more reliable basis for making clinical decisions.
引用
- Hirt J, Pieper D, Becker M, et al. Clinical study report data did not substantially alter point estimates but improved precision in a nephrology systematic review. J Clin Epidemiol. 2025. PMID: 40581169. doi:10.1016/j.jclinepi.2025.111890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。